<DOC>
	<DOCNO>NCT00004076</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness PNU 166148 treat patient metastatic solid tumor respond previous treatment .</brief_summary>
	<brief_title>PNU 166148 Treating Patients With Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety profile , maximum tolerate dose , dose limit toxicity PNU 166148 patient metastatic , refractory solid tumor . II . Define recommend dose PNU 166148 Phase II study . III . Determine pharmacokinetic profile molecular weight distribution PNU 166148 pharmacokinetic profile free camptothecin patient . IV . Assess evidence antitumor activity patient treat regimen . OUTLINE : This dose escalation , open label , multicenter study . Patients receive PNU 166148 IV 30 minute . Treatment repeat every 4 week 3-6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PNU 166148 maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 3-6 patient experience dose limit toxicity . Patients follow 30 day , monthly thereafter resolution adverse event occur study attributable study drug , unless another antitumor treatment begin . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic , refractory solid tumor curative therapy exist No 2 prior chemotherapy regimens metastatic disease No prior high dose chemotherapy regimen require bone marrow transplantation peripheral blood stem cell transplantation No hematologic malignancies No brain leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal ( great 1.5 time upper limit normal ( ULN ) liver metastasis present ) SGOT SGPT normal ( great 5 time ULN liver metastasis present ) Hepatitis B negative Renal : Creatinine le 1.5 mg/dL EDTA clearance great 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study No severe concurrent nonmalignant disease would preclude protocol therapy HIV negative No AIDS relate illness No mental incapacity PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior immunotherapy recover No concurrent biological response modifier therapy immunotherapy No concurrent prophylactic growth factor Chemotherapy : See Disease Characteristics No prior camptothecins ( e.g. , irinotecan topotecan ) At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy recover No concurrent corticosteroid use anticancer therapy No concurrent hormonal therapy Radiotherapy : No prior radiotherapy great 25 % bone marrow At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational drug participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>